Welcome to World Class Retina Care

Our practice was established in 1980 in central Phoenix. Since then, we have grown to include more than 35 locations throughout Arizona, providing improved access to the highest quality medical care. We are proud to have become Arizona’s largest and most experienced ophthalmology practice focused specifically on the diagnosis and management of the retina and vitreous.

At RCA, we believe in providing you with professional, attentive, and personal care while utilizing the latest technology and treatments. We accept new patients every day, and urgent or emergency referrals are seen the same day.

Find Your Location Today

February Is Age-Related Macular Degeneration Awareness Month

 

Learn More About AMD

Age-Related Macular Degeneration (AMD) is the leading cause of blindness among older Americans, but new treatments have dramatically changed the course of this disease over the last 10 years, making AMD more manageable than ever before.

During AMD Awareness Month in February, the American Academy of Ophthalmology is reminding people with AMD that they can save their vision thanks to recent treatment advances, but early detection is a critical first step.

Latest News From RCA

Retinal Research Institute: New FDA-Approved Stem Cell Research Study

Information for Patients with Geographic Atrophy Related to Dry Age-Related Macular Degeneration – An Experimental Treatment of Severe Vision Loss from Advanced Dry Age-Related Macular Degeneration. What is the Investigational treatment? This investigational treatment includes using an implant to replace some of the cells in the retina that have been lost or damaged due to… Read More »

Dr. Pravin U. Dugel – Modern Retina from Ophthalmology Times

These novel strategies may change DME treatment paradigm By: Michelle Dalton, ELS; Reviewed by Pravin U. Dugel, MD There is no denying that the anti-vascular endothelial growth factor A (anti-VEGF-A) monotherapy has “absolutely revolutionized our treatment of diabetic macular edema (DME).” However, there is a subset of patients in whom the anti-VEGFs are not an… Read More »

Dr. Pravin Dugel: Brolucizumab: A New Anti-VEGF Agent For Wet AMD

In this interview from AAO 2017, Dr. Pravin Dugel outlines the results of two phase 3 trials of brolucizumab, a novel anti-VEGF agent for treating neovascular AMD. Brolucizumab is the smallest active unit of a human monoclonal antibody, which allows for concentrated molar dosing. The two trials, dubbed HAWK and HARRIER, suggest that extended dosing is viable.… Read More »